and diastereoselective functionalization of the secondary over the tertiary α-C–H bond of 2-substituted pyrrolidines is first realized. Subsequent intermolecular addition of a nucleophile to the generated N,O-acetal and cleavage of the aromatic substituent leads to 2,5-disubstitutedpyrrolidines.
Gly1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
申请人:Bloomfield Jonathon Nic
公开号:US20050267152A1
公开(公告)日:2005-12-01
The present invention relates to glycine transporter inhibiting compounds of formula (I):
for treating disorders mediated by GlyT1, wherein R
1
—R
9
are as in the description.
GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS
申请人:SMITHKLINE BEECHAM PLC
公开号:EP1455777A1
公开(公告)日:2004-09-15
[EN] GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS<br/>[FR] INHIBITEURS DE TRANSPORTEURS GLYT1 ET UTILISATONS DE CEUX-CI DANS LE TRAITEMENT DE TROUBLES NEUROLOGIQUES ET NEUROPSYCHIATRIQUES
申请人:SMITHKLINE BEECHAM PLC
公开号:WO2003055478A1
公开(公告)日:2003-07-10
The present invention relates to glycine transporter inhibiting compounds of formula (I): for the manufacture of a medicament for treating disorders mediated GlyT1, wherein R1-R9 are as in the description.